More articles (current) News & expert insights (recommended)
Skip to main content
Read Article
Read Article
Read Article 
Read Article
Read Article
Read Article
Insights
There is always something exciting happening at Lockton. Here are just a few from our newsroom.
1 / 6
— Alert
DOL proposes updated e-disclosure rule for ERISA group health plans
On July 23, 2026, the DOL’s Employee Benefits Security Administration (EBSA) published a proposed rule on Electronic Disclosure by Group Health Plans Under ERISA, which seeks to create a new, additional safe harbor for group health plan administrator …
— Articles
Cyber Risk Discussion Guide for Boardrooms
Cybersecurity is no longer just a technology issue, it is a boardroom responsibility with direct implications for business resilience, regulatory compliance, financial performance, and stakeholder trust. The Cyber Risk Discussion Guide for Boardrooms …
— Articles
HEALTHCARE
Advancing transparency, trust, and organizational resilience in healthcare
Patients visit healthcare organizations expecting to receive treatments or therapies that improve their health or offer relief from an illness. While the vast majority of patients receive safe, effective care and experience positive outcomes, unexpec …
— Articles
Common crime insurance losses for private equity portfolio companies
Today’s private equity environment puts a premium on speed, scale, and value creation. Those dynamics, while potentially lucrative for private equity firms and their investors, can also increase crime risk for portfolio companies they own. Portfolio …
— Articles
New social media litigation risks bring governance and insurance into focus
In March 2026, a California jury ordered Meta and YouTube to pay $6 million to a plaintiff who alleged that childhood use of social media platforms contributed to addiction, anxiety, depression, and other mental health harms. For companies of the def …
— Articles
Cell & gene therapy: Preparing for the next phase of employer health plan risk
Cell and gene therapies are often viewed as an emerging wave of multimillion-dollar costs for employer health plans. While these therapies can exceed $2 million-$4 million per treatment, current employer exposure remains limited because utilization h …
